



The Corporate Relationship Department,
BSE Limited
1st Floor , New Trading Ring Rotunda
Building, P.J. Towers
Dalal Street,
Mumbai 400 001

National Stock Exchange of India Limited
“Exchange Plaza”
Bandra-Kurla Complex
Bandra (E)
Mumbai 400 051

Scrip Code- 503806

Scrip Code-SRF

SRF/SEC/BSE/NSE

25.01.2022

Dear Sirs,

Subject: Capital Expenditure proposal approved by the Board

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held on January 25, 2022 has approved project to create Pharma Intermediates Plant for undertaking precursor processes for production of Pharma products at Dahej at a cost of Rs. 190 Crores.

Information as required under the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

a) existing capacity;	Not Applicable
b) existing capacity utilization	Not Applicable
c) proposed capacity addition;	Not Applicable
d) period within which the proposed capacity is to be added	30 th November, 2022
e) investment required	Rs. 190 Crores
f) mode of financing	Mix of debt and internal accruals
g) rationale	To tap new and upcoming business opportunities in the pharma space

Thanking you,
Yours faithfully,

For SRF LIMITED

Rajat Lakhpal
VP (Corporate Compliance) & Company Secretary

SRF LIMITED
Block-C Sector 45
Gurugram 122 003
Haryana India
Tel: +91-124—4354400
Fax: +91-124—4354500
E-mail: info@srf.com
Website: www.srf.com
Regd. Office:
Unit No. 236 & 237, 2nd Floor
DLF Galleria, Mayur Place
Noida Link Road
Mayur Vihar Phase 1 Extension
Delhi 110091